JNCE Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2023 @ 23:00):

Stats
Dzisiejszy wolumen	11.60M
Średni wolumen	3.47M
Kapitalizacja rynkowa	98.95M
EPS	$0 ( 2024-03-08 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.958
ATR14	$0.0820 (4.36%)

Insider Trading

Date	Person	Action	Amount	type
2023-05-03	Concentra Biosciences, Llc	Buy	10 000	Common Stock
2023-05-03	Tang Kevin C	Buy	10 000	Common Stock
2023-05-03	Tang Kevin C	Sell	5 300 087	Common Stock
2023-05-03	Concentra Biosciences, Llc	Buy	0	Common Stock
2023-05-03	Salter-cid Luisa	Sell	20 000	Stock Option (Right to Buy)

INSIDER POWER
-96.71
Last 98 transactions
Buy: 1 025 987 \| Sell: 8 913 091

Wolumen Korelacja

Długi: -0.01 (neutral)

Krótki: -0.19 (neutral)

Signal:(59.515) Neutral

Jounce Therapeutics Inc Korelacja

10 Najbardziej pozytywne korelacje
SVAC	0.941
MLAI	0.934
QADB	0.93
DXPE	0.928
MPRA	0.928
IMPPP	0.928
SGC	0.924
VITL	0.924
IVCB	0.924
AIRG	0.923

10 Najbardziej negatywne korelacje
LWAC	-0.964
FRBA	-0.956
AMAL	-0.953
CCB	-0.953
CVBF	-0.95
RETO	-0.95
BIVI	-0.948
RBB	-0.946
FBMS	-0.946
MYFW	-0.944

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Jounce Therapeutics Inc Korelacja - Waluta/Towar

0.80
( moderate )

0.82
( strong )

0.00
( neutral )

0.90
( very strong )

-0.03
( neutral )

-0.52
( weak negative )

Jounce Therapeutics Inc Finanse

Annual	2022
Przychody:	$82.00M
Zysk brutto:	$82.00M (100.00 %)
EPS:	$-0.990

FY	2022
Przychody:	$82.00M
Zysk brutto:	$82.00M (100.00 %)
EPS:	$-0.990

FY	2021
Przychody:	$26 907.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.00182

FY	2020
Przychody:	$62.34M
Zysk brutto:	$62 339.00 (0.10 %)
EPS:	$-1.240

Financial Reports:

No articles found.

Jounce Therapeutics Inc

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.